Hong Zheng , Zhang-Yang Xu , Ting Hu , Yi-Lin Wu , Chen-Wei Huang , Jia-Mei Li , Zhi-Yong Cao , Wei Wang , Chun-Lei Jiang , Wen-Jun Su
{"title":"RIPK3-MLKL dependent necroptosis mediates depressive-like behavior by facilitating neuroinflammation","authors":"Hong Zheng , Zhang-Yang Xu , Ting Hu , Yi-Lin Wu , Chen-Wei Huang , Jia-Mei Li , Zhi-Yong Cao , Wei Wang , Chun-Lei Jiang , Wen-Jun Su","doi":"10.1016/j.jneuroim.2025.578643","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Neuroinflammation is a critical pathophysiological mechanism of depression. But the sources and processes involved remain unclear. Recent reports suggest that necroptosis with pro-inflammatory properties may facilitate inflammation. Therefore, we investigated the potential role of necroptosis-associated neuroinflammation in depression.</div></div><div><h3>Methods</h3><div>Depression model mice induced by intraperitoneal injection of lipopolysaccharide (LPS) were treated with RIPK1 inhibitor Necrostatin-1 s (Nec-1 s, 6 mg/kg), RIPK3 inhibitor GSK′872 (6 mg/kg) or intracerebroventricular injection of MLKL inhibitor GW806742X (5 μL of 200 μmol/L). Depressive-like behaviors were assessed using sucrose preference test and tail suspension test. Serum inflammatory cytokines were detected by ELISA, while glial biomarkers were determined by western blots. Hematoxylin & eosin and immunohistochemical staining were utilized to identify morphological characteristics of necroptotic cells in the hippocampus and prefrontal cortex. Further, specific molecules involved in necroptotic pathway were measured by immunoblots.</div></div><div><h3>Results</h3><div>Mice treated with LPS exhibited depressive-like behaviors, as well as increased inflammatory cytokines, enhanced MLKL phosphorylation, and decreased cleaved Caspase-8 levels in hippocampus. GSK′872 rather than Nec-1 s exhibited significant antidepressant effects. Although necroptosis was present in both the hippocampus and prefrontal cortex, neuroinflammation was mainly manifested in the hippocampus. Additionally, GSK′872 restored the elevated levels of IL-1β, TNF-α, and HMGB1 in the serum and hippocampus of model mice, and simultaneously ameliorated necroptosis. However, neither GSK’872 nor Nec-1 s had sufficient effect on Caspase-8 and microgliosis. Furthermore, intracerebroventricular injection of GW806742X improved depressive-like behavior and neuroinflammation in hippocampus.</div></div><div><h3>Conclusion</h3><div>This study provides novel evidence that hippocampal RIPK3-MLKL-dependent necroptosis mediates depressive-like behavior induced by inflammatory stress. During this process, necroptosis may facilitate neuroinflammation by promoting the release of HMGB1. Interventions targeting this pathway may help treat depression with an inflammatory phenotype.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"405 ","pages":"Article 578643"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572825001249","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Neuroinflammation is a critical pathophysiological mechanism of depression. But the sources and processes involved remain unclear. Recent reports suggest that necroptosis with pro-inflammatory properties may facilitate inflammation. Therefore, we investigated the potential role of necroptosis-associated neuroinflammation in depression.
Methods
Depression model mice induced by intraperitoneal injection of lipopolysaccharide (LPS) were treated with RIPK1 inhibitor Necrostatin-1 s (Nec-1 s, 6 mg/kg), RIPK3 inhibitor GSK′872 (6 mg/kg) or intracerebroventricular injection of MLKL inhibitor GW806742X (5 μL of 200 μmol/L). Depressive-like behaviors were assessed using sucrose preference test and tail suspension test. Serum inflammatory cytokines were detected by ELISA, while glial biomarkers were determined by western blots. Hematoxylin & eosin and immunohistochemical staining were utilized to identify morphological characteristics of necroptotic cells in the hippocampus and prefrontal cortex. Further, specific molecules involved in necroptotic pathway were measured by immunoblots.
Results
Mice treated with LPS exhibited depressive-like behaviors, as well as increased inflammatory cytokines, enhanced MLKL phosphorylation, and decreased cleaved Caspase-8 levels in hippocampus. GSK′872 rather than Nec-1 s exhibited significant antidepressant effects. Although necroptosis was present in both the hippocampus and prefrontal cortex, neuroinflammation was mainly manifested in the hippocampus. Additionally, GSK′872 restored the elevated levels of IL-1β, TNF-α, and HMGB1 in the serum and hippocampus of model mice, and simultaneously ameliorated necroptosis. However, neither GSK’872 nor Nec-1 s had sufficient effect on Caspase-8 and microgliosis. Furthermore, intracerebroventricular injection of GW806742X improved depressive-like behavior and neuroinflammation in hippocampus.
Conclusion
This study provides novel evidence that hippocampal RIPK3-MLKL-dependent necroptosis mediates depressive-like behavior induced by inflammatory stress. During this process, necroptosis may facilitate neuroinflammation by promoting the release of HMGB1. Interventions targeting this pathway may help treat depression with an inflammatory phenotype.
期刊介绍:
The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.